Earnings History Data for BioCryst Pharmaceuticals, Inc. (BCRX) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
26-02-2024	PM		BCRX	BioCryst Pharmaceuticals, Inc.	1,190	-0.28	-0.24	-0.38	BioCryst Pharmaceuticals reports Q4 results [2/26/2024 7:02 AM]	5.79	0.08 (1.31%)	5.74	0.03 (0.53%)	4.82 - 9.20	3,286,403	3,290,000	121,920
BioCryst Pharmaceuticals reports Q4 results [2/26/2024 7:02 AM]
02-11-2023	PM		BCRX	BioCryst Pharmaceuticals, Inc.	1,040	-0.19	-0.25	-0.23	BioCryst Pharmaceuticals Non-GAAP EPS of -$0.19 in-line, revenue of $86.74M beats by $0.68M [11/2/2023 7:13 AM]	5.64	-0.09 (-1.57%)	5.64	0.0 (0.00%)	5.21 - 14.20	4,570,958	2,590,000	19,333
BioCryst Pharmaceuticals Q3 2023 Earnings Preview [11/1/2023 1:08 PM] BioCryst Pharmaceuticals Non-GAAP EPS of -$0.19 in-line, revenue of $86.74M beats by $0.68M [11/2/2023 7:13 AM]
03-08-2023	PM		BCRX	BioCryst Pharmaceuticals, Inc.	1,320	-0.24	-0.25	-0.32	BioCryst Pharmaceuticals Non-GAAP EPS of -$0.24 misses by $0.03, revenue of $82.49M beats by $1.06M [8/3/2023 7:06 AM]	7.07	0.12 (1.73%)	7.15	0.20 (2.88%)	6.78 - 15.43	5,282,305	2,880,000	31,126
BioCryst Pharmaceuticals Q2 2023 Earnings Preview [8/2/2023 2:21 PM] BioCryst Pharmaceuticals Non-GAAP EPS of -$0.24 misses by $0.03, revenue of $82.49M beats by $1.06M [8/3/2023 7:06 AM]
03-05-2023	PM	7:00 AM ET (May 3)	BCRX	BioCryst Pharmaceuticals, Inc.	1,420	-0.28	-0.30	-0.40	BioCryst Pharmaceuticals GAAP EPS of -$0.28 beats by $0.03, revenue of $68.78M misses by $2.66M [5/3/2023 7:05 AM]	8.29	0.92 (12.42%)	8.09	0.72 (9.77%)	7.20 - 15.43	6,316,181	2,680,000	59,034
BioCryst Pharmaceuticals GAAP EPS of -$0.28 beats by $0.03, revenue of $68.78M misses by $2.66M [5/3/2023 7:05 AM] BioCryst gains 14% most since February after Q1 2023 results [5/3/2023 2:55 PM]
21-02-2023	PM	7:00 AM ET (Feb 21)	BCRX	BioCryst Pharmaceuticals, Inc.	1,850	-0.38	-0.19	-0.40	BioCryst Pharmaceuticals Non-GAAP EPS of -$0.38 misses by $0.18, revenue of $79.5M beats by $5.32M [2/21/2023 7:03 AM]	8.62	-1.58 (-15.54%)	8.75	-1.45 (-14.22%)	7.61 - 18.60	12,233,261	2,050,000	203,973
BioCryst Pharmaceuticals Q4 2022 Earnings Preview [2/20/2023 10:22 AM] BioCryst Pharmaceuticals Non-GAAP EPS of -$0.38 misses by $0.18, revenue of $79.5M beats by $5.32M [2/21/2023 7:03 AM] BioCryst at nine-month low as Q4 bottom-line disappoints [2/21/2023 10:42 AM]
01-11-2022	PM	7:00 AM ET (Nov 1)	BCRX	BioCryst Pharmaceuticals, Inc.	2,610	-0.23	-0.32	-0.33	BioCryst Pharmaceuticals reports Q3 earnings beat; updates FY22 guidance [11/1/2022 7:06 AM]	11.91	-1.43 (-10.75%)	12.13	-1.22 (-9.14%)	7.61 - 19.99	9,139,924	2,830,000	474,986
BioCryst Pharmaceuticals reports Q3 earnings beat; updates FY22 guidance [11/1/2022 7:06 AM] BioCryst falls 11% despite Q3 beat (update) [11/1/2022 1:59 PM] BioCryst Reports Third Quarter 2022 Financial Results and Upcoming Key Milestones [Nov-01-22 07:00AM]
04-08-2022	PM	7:00 AM ET (Aug 4)	BCRX	BioCryst Pharmaceuticals, Inc.	2,060	-0.32	-0.36	-0.24	BioCryst Pharmaceuticals GAAP EPS of -$0.32 beats by $0.03, revenue of $65.53M beats by $1.7M [8/4/2022 7:06 AM]	13.71	2.56 (22.96%)	12.70	1.55 (13.90%)	7.61 - 19.99	10,369,994	1,910,000	611,861
BioCryst Pharmaceuticals Q2 2022 Earnings Preview [8/3/2022 1:29 PM] BioCryst Pharmaceuticals GAAP EPS of -$0.32 beats by $0.03, revenue of $65.53M beats by $1.7M [8/4/2022 7:06 AM] BioCryst adds 16% as FDA lifts clinical hold on kidney disease program [8/4/2022 9:09 AM]
05-05-2022	PM	7:00 AM ET (May 5)	BCRX	BioCryst Pharmaceuticals, Inc.	1,780	-0.40	-0.39	-0.36	BioCryst Pharmaceuticals GAAP EPS of -$0.40 misses by $0.03, revenue of $49.92M misses by $1.44M [5/5/2022 7:10 AM]	9.75	-0.43 (-4.22%)	9.80	-0.38 (-3.73%)	9.18 - 19.99	4,758,291	4,764,680	173,704
BioCryst Pharmaceuticals Q1 2022 Earnings Preview [5/4/2022 12:57 PM] BioCryst Pharmaceuticals GAAP EPS of -$0.40 misses by $0.03, revenue of $49.92M misses by $1.44M [5/5/2022 7:10 AM] BioCryst posts Q1 miss; FDA places partial hold on program for factor D inhibitor [5/5/2022 7:48 AM] BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [May-04-22 04:15PM] BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones [May-05-22 07:00AM] BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Lags Revenue Estimates [May-05-22 08:25AM] BioCryst Pharmaceuticals (BCRX) Q1 2022 Earnings Call Transcript [May-05-22 03:00PM]
23-02-2022	PM	7:00 AM ET (Feb 23)	BCRX	BioCryst Pharmaceuticals, Inc.	3,370	-0.40	-0.31	-0.34	BioCryst Pharmaceuticals Non-GAAP EPS of -$0.40 misses by $0.11, revenue of $47.2M misses by $3.28M [2/23/2022 7:03 AM]	16.71	-1.04 (-5.86%)	16.79	-0.96 (-5.41%)	9.23 - 19.99	4,802,653	3,880,000	244,555
BioCryst Pharmaceuticals Q4 2021 Earnings Preview [2/22/2022 11:23 AM] BioCryst Pharmaceuticals Non-GAAP EPS of -$0.40 misses by $0.11, revenue of $47.2M misses by $3.28M [2/23/2022 7:03 AM] BioCryst slips after lower-than-expected Q4 2021 results [2/23/2022 8:14 AM] BioCryst Begins Patient Enrollment in RENEW Proof-of-Concept Trial Evaluating BCX9930 for Patients with Renal Complement-mediated Diseases [Feb-22-22 07:00AM] BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key Milestones [Feb-23-22 07:00AM] BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Misses Revenue Estimates [Feb-23-22 08:15AM] Why BioCryst Pharmaceuticals Stock Slid Today [Feb-23-22 06:30PM]
03-11-2021	PM	7:00 AM ET (Nov 3)	BCRX	BioCryst Pharmaceuticals, Inc.	2,740	-0.33	-0.30	-0.26	BioCryst Pharmaceuticals EPS misses by $0.03, beats on revenue [11/3/2021 7:03 AM]	12.40	-2.74 (-18.10%)	13.93	-1.21 (-7.99%)	3.74 - 18.48	11,905,297	2,020,000	419,526
BioCryst Pharmaceuticals Q3 2021 Earnings Preview [11/2/2021 11:45 AM] BioCryst slips despite better than expected revenue for Q3 [11/3/2021 7:58 AM] BioCryst Pharmaceuticals EPS misses by $0.04, beats on revenue [11/3/2021 7:03 AM] BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Nov-02-21 07:00AM] BioCryst Reports Third Quarter 2021 Financial Results and Upcoming Key Milestones [Nov-03-21 07:00AM] BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates [Nov-03-21 08:35AM] Here's Why BioCryst Pharmaceuticals Stock Is Losing Ground Today [Nov-03-21 01:13PM] BioCryst Pharmaceuticals (BCRX) Q3 2021 Earnings Call Transcript [Nov-03-21 02:31PM]
05-08-2021	PM	7:00 AM ET (Aug 5)	BCRX	BioCryst Pharmaceuticals, Inc.	2,980	-0.24	-0.22	-0.24	BioCryst Pharmaceuticals EPS misses by $0.01, beats on revenue [8/5/2021 7:06 AM]	17.64	1.38 (8.49%)	15.70	-0.56 (-3.44%)	3.30 - 17.81	6,903,628	2,390,000	1,323,704
BioCryst Pharmaceuticals EPS misses by $0.01, beats on revenue [8/5/2021 7:06 AM] BioCryst shares surge on ORLADEYO driven Q2 topline beat [8/5/2021 7:44 AM] BioCryst Reports Second Quarter 2021 Financial Results and Upcoming Key Milestones [Aug-05-21 07:00AM] Why BioCryst Pharmaceuticals Rose 8% on Thursday [Aug-05-21 04:08PM]
06-05-2021	PM	7:00 AM ET (May 6)	BCRX	BioCryst Pharmaceuticals, Inc.	1,960	-0.36	-0.24	-0.24	BioCryst Pharmaceuticals EPS misses by $0.08, beats on revenue [5/6/2021 7:05 AM]	12.94	2.26 (21.16%)	12.84	-0.10 (-0.77%)	3.30 - 14.24	17,302,298	2,540,000	43,442
BioCryst Pharmaceuticals EPS misses by $0.08, beats on revenue [5/6/2021 7:05 AM] BioCryst shares surge 21% on Evercore upgrade, revenue beat [5/6/2021 4:00 PM] BioCryst to Present at Upcoming Investor Conferences [May-05-21 07:00AM] BioCryst Pharmaceuticals, Inc. to Host Earnings Call [May-06-21 06:30AM] BioCryst Reports First Quarter 2021 Financial Results and Upcoming Key Milestones [May-06-21 07:00AM] BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates [May-06-21 09:05AM] Why BioCryst Pharmaceuticals Stock Is Soaring Today [May-06-21 11:06AM]
25-02-2021	PM	7:00 AM ET (Feb 25)	BCRX	BioCryst Pharmaceuticals, Inc.	1,960	-0.34	-0.25	-0.02	BioCryst Pharmaceuticals EPS misses by $0.09, misses on revenue [2/25/2021 7:11 AM]	10.50	-1.30 (-11.05%)	11.07	-0.74 (-6.27%)	1.58 - 12.90	6,987,657	6,620,299	459,861
BioCryst Pharmaceuticals EPS misses by $0.09, misses on revenue [2/25/2021 7:11 AM] BioCryst's ORLADEYO nabs CHMP positive recommendation in hereditary angioedema [2/25/2021 4:26 PM] BioCryst Reports Fourth Quarter and Full Year 2020 Financial Results and Upcoming Key Milestones [Feb-25-21 07:00AM] BioCryst Pharmaceuticals, Inc. to Host Earnings Call [Feb-25-21 06:30AM]
05-11-2020	PM	7:00 AM ET (Nov 5)	BCRX	BioCryst Pharmaceuticals, Inc.	697.43	-0.26	-0.25	-0.34	BioCryst Pharmaceuticals EPS misses by $0.01, beats on revenue [11/5/2020 7:04 AM]	4.24	-0.04 (-0.82%)	4.24	0.0 (0.00%)	1.38 - 6.29	5,662,020	4,450,424	62,520

06-08-2020	PM	7:00 AM ET (Aug 6)	BCRX	BioCryst Pharmaceuticals, Inc.	776.16	-0.24	-0.28	-0.34	BioCryst Pharmaceuticals EPS beats by $0.02, beats on revenue [8/6/2020 7:08 AM]	4.03	-0.18 (-4.39%)	4.01	-0.20 (-4.75%)	1.38 - 6.29	5,862,303	6,405,615	988,592

06-05-2020	PM		BCRX	BioCryst Pharmaceuticals, Inc.	606.23	-0.24	-0.26	-0.28	BioCryst Pharmaceuticals EPS beats by $0.01, beats on revenue [5/6/2020 7:03 AM]	3.95	0.02 (0.51%)	4.02	0.07 (1.77%)	1.38 - 8.15	12,435,959	14,352,814	276,612